Home
About Us
FAQ
Contact Us
Media Tools
ExpertConnect App
MyExpertNet
University Partners
Becoming a Partner
Key Organizations
Search Assistance
Help
Expert Profile
Views:
23
Share
QR code
Edit Profile
Long Dang
Md
PH-MEDICINAL CHEMISTRY | COLLEGE-PHARMACY
View:
Select
All (all in one)
Research Terms and Keywords
Publications
Co-Investigator Network
Websites
Contact
All
Research
Publications
Network
Websites
Contact
Research Terms & Keywords
Research Terms
Hematology
Research Projects
Ends
Title
08-2019
Novel Targeted Anticancer Agents from Marine Cyanobacteria
Novel Targeted Anticancer Agents from Marine Cyanobacteria
01-2018
A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer
A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer
10-2017
A RANDOMIZED PHASE 2 TRIAL OF AXITINIB AND TRC105 VERSUS AXITINIB ALONE (INCLUDING A LEAD-IN PHASE 1B DOSE-ESCALATION PORTION) IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA
A RANDOMIZED PHASE 2 TRIAL OF AXITINIB AND TRC105 VERSUS AXITINIB ALONE (INCLUDING A LEAD-IN PHASE 1B DOSE-ESCALATION PORTION) IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA
06-2017
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFR+? Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFR+? Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
03-2017
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma
01-2017
HOG:GU09-145/PHASE I OF: Phase I/II Study of BNC105P in Combination with Everolimus of Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
HOG:GU09-145/PHASE I OF: Phase I/II Study of BNC105P in Combination with Everolimus of Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
02-2013
Randomized, Double-Blind, Phase 3 Trial to
Randomized, Double-Blind, Phase 3 Trial to
06-2011
CDX1307-03:A Phase II, Open-Label, Controlled, Randomize
CDX1307-03:A Phase II, Open-Label, Controlled, Randomize
Publications
Search Google Scholar for Long Dang
Co-Investigator Network
Brian Law
Associate Professor
University of Florida
MD-PHARMACOLOGY / THERAPEUTICS, College-Medicine
bklaw@ufl.edu
Hendrik Luesch
Professor and Chair, Debbie And Sylvia DeSantis Chair In Natural Products Drug Discovery And Development
University of Florida
PH-MEDICINAL CHEMISTRY, College-Pharmacy
luesch@ufl.edu
Bruce Stechmiller
Clinical Associate Professor
University of Florida
MD-HEMATOLOGY/ONCOLOGY, College-Medicine
bruce.stechmiller@medicine.ufl.edu
Websites
Search Google Scholar for Long Dang
Contact Information
danglh@ufl.edu
3522739094
1600 SW ARCHER RD GAINESVILLE, FL 32610-3003
Profile QR code
What is this?
Keyword Search
Please enter valid search criteria.
Search
Centers
Experts
Projects
Speakers
Stories
Technologies
Videos
University
All Universities
Florida A&M University
Florida Atlantic University
Florida Gulf Coast University
Florida Institute of Technology
Florida International University
Florida State University
University of Central Florida
University of Florida
University of Miami
University of North Florida
University of South Florida
University of West Florida
Browse by STEM
Biotechnology
Computer Science
Energy
Engineering
Environmental Sciences
Information Science
Life Sciences
Mathematics
Medical Sciences
Military Sciences
Natural Sciences
Physical Sciences
Plant Sciences
Science
Space Sciences
Technology
Transportation
